Developing a Complex ex Vivo Endometrial Tissue Model to Improve Endometriosis Care

Endometriosis Clinical Trial

— OTEndo  

Official title:

Developing a Complex ex Vivo Endometrial Tissue Model Based on Patient Biopsies to Assess and Optimise the Response to Current and Potential Treatments for Endometriosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06331676
• Other study ID #: 69HCL23_1120
• Secondary ID: 2023-A02339-36
• Status: Not yet recruiting
• Phase: N/A
• Start date: April 2024
• Est. completion date: October 2025

Study information

• Verified date: March 2024
• Source: Hospices Civils de Lyon
• Contact: Charles-André PHILIP, M.D., PhD
• Phone: 04 27 85 51 70
• Email: charles-andre.philip01[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Endometriosis is a chronic gynaecological disease characterised by the growth of endometrium outside the uterus. It affects 10% of childbearing age women.

There is no cure for endometriosis. Hormonal treatments should be the first line therapy. The benefit-risk ratio of symptomatic treatment with hormone therapy varies greatly from one woman to another. The pathophysiology of endometriosis and the mechanisms of action of these treatments are still poorly understood. This may be due to the lack of an optimal experimental model for studying the disease.

The aim of this project is to develop a complex ex vivo endometrial model recapitulating the organisation and properties of the human endometrium using innovative tissue bioengineering methods. This model will make it possible to develop a pre-clinical approach that predicts individual response to different types of hormonal treatment in order to optimise therapeutic choices and provide a better understanding of the effects of these treatments.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 45
• Est. completion date: October 2025
• Est. primary completion date: October 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Female

• People aged between 18 and 50

• Person who has or has had hormonal contraceptive treatment

• A person who has given written consent

• Person diagnosed with a benign gynaecological pathology not affecting the endometrium and requiring hysterectomy, hysteroscopy or laparoscopy or with a diagnosis of endometriosis and requiring laparoscopy or hysterectomy

• Person affiliated to the french social security

Exclusion Criteria:

• Pregnant at the time of sampling or within 3 months prior to sampling

• Breast-feeding women

• Women undergoing physiological menopause

• Anyone who has received hormonal treatment with hormones other than steroids in the three months prior to sampling

• Anyone with a non-hormonal contraceptive intrauterine device (copper coil)

• Anyone with a personal history of cancer of the breast, ovary, endometrium or cervix

• People with Lynch syndrome

• Persons under legal protection (guardianship, curatorship)

• Persons deprived of their liberty by judicial or administrative decision

• Persons with a body mass index (BMI) of less than 18.5 or more than 30

Related Conditions & MeSH terms

• Endometriosis

Intervention

Procedure:
• Tissue collection
Eutopic and ectopic endometrium biopsies, additional blood and peritoneal fluid sampling

Other:
• Data collection
Questionnaire on menstrual health and history of hormone treatments for the research purpose

Locations

Country	Name	City	State
France	Hôpital Femme Mère Enfant / GHE	Bron
France	Hôpital de la Croix-Rousse / GHN	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Viability of all the cells forming the complex endometrial tissue generated ex vivo by tissue bioengineering.	The viability of all the cells forming the complex endometrial tissue generated ex vivo by tissue bioengineering will be assessed either by flow cytometry (labelling with propidium iodide or 7-AAD) or by immunofluorescence (with lipophilic carbocyanine dyes). The scientists involved in the project reserve the right to modify these labelling techniques and the markers mentioned, depending on the technical and logistical challenges encountered during the tissue bioengineering stages.	through study completion, an average of 18 months
Secondary	Change in protein expression	Comparing changes in protein expression in the model of complex endometrial tissue generated ex vivo by tissue bioengineering (eutopic endometrium) in each donor, between control and endometriosis groups and between eutopic and ectopic endometrium in endometriosis group.	through study completion, an average of 18 months
Secondary	Change in gene expression	Comparing changes in gene expression in the model of complex endometrial tissue generated ex vivo by tissue bioengineering (eutopic endometrium) in each donor, between control and endometriosis groups and between eutopic and ectopic endometrium in endometriosis group.	through study completion, an average of 18 months
Secondary	Change in inflammation	The concentration (expressed in pg/gl) of the following cytokines will be measured using Luminex technology (Bio-Plex 200 analyser): Interleukin (IL) 1ß, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40/p70, IL-13, IL-15, IL-17, Tumor Necrosis Factor TNFa, interferons (IFN) IFN-a, IFN-?, Granulocyte-Macrophage Colony Stimulating Factor GM-CSF, Macrophage Inflammatory Protein MIP-1a, MIP-1ß, Interferon gamma-induced protein 10 IP-10, Eotaxin, RANTES, and Monocyte Chemoattractant Protein-1 MCP-1.; Changes in these inflammation markers concentration in the model of complex endometrial tissue generated ex vivo by tissue bioengineering (eutopic endometrium) in each donor, between control and endometriosis groups and between eutopic and ectopic endometrium in endometriosis group will be assessed.	through study completion, an average of 18 months
Secondary	Change in histological tissue structure	Comparing changes in histological tissue structure (density of glands open to the lumen and glands located in the basal layer of the endometrium expressed in number of glands/cm3 of tissue, measured with an haematoxiline-eosin stainings and using Image J software) in the model of complex endometrial tissue generated ex vivo by tissue bioengineering (eutopic endometrium) in each donor, between control and endometriosis groups and between eutopic and ectopic endometrium in endometriosis group.	through study completion, an average of 18 months
Secondary	Change in histological tissue structure	Comparing changes in histological tissue structure (thickness of the endometrium expressed in micrometer) in the model of complex endometrial tissue generated ex vivo by tissue bioengineering (eutopic endometrium) in each donor, between control and endometriosis groups and between eutopic and ectopic endometrium in endometriosis group.	through study completion, an average of 18 months
Secondary	Change in tissue elasticity	Comparing changes in tissue elasticity by assessing the speed of shear waves in the model of complex endometrial tissue generated ex vivo by tissue bioengineering (eutopic endometrium) in each donor, between control and endometriosis groups and between eutopic and ectopic endometrium in endometriosis group.	through study completion, an average of 18 months
Secondary	Change in steroid hormone physiology	Measurement of steroid hormones concentration levels in blood and comparison between control and endometriosis groups.; Steroid hormones assays will be carried out using ELISA® technologies. The following hormones will be measured: prolactin, Luteinizing Hormone (LH), estradiol (E2), estrone, progesterone and Sex hormone-binding globulin SHBG. The unit of measurement is pg/ml for all hormones.	At baseline
Secondary	Steroid hormones in peritoneal fluid	Measurement of steroid hormones concentration levels in peritoneal fluid and comparison between control and endometriosis groups.; Steroid hormones assays will be carried out using ELISA® technologies. The following hormones will be measured: prolactin, Luteinizing Hormone (LH), estradiol (E2), estrone, progesterone and Sex hormone-binding globulin SHBG. The unit of measurement is pg/ml for all hormones.	At baseline